Metadon

Methadone Hydrochloride, the active ingredient in Metadon, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the management of opioid dependence maintenance therapy and for the relief of severe chronic pain in adult patients. As a full μ‑opioid receptor agonist with additional NMDA antagonism, it provides long‑lasting analgesic effect and helps stabilize individuals undergoing opioid substitution programs. The medication is administered orally and is classified as a Schedule II controlled substance in many jurisdictions, reflecting its potential for dependence and the need for careful medical supervision.

GNH USA supplies Metadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone Hydrochloride is used in opioid‑related conditions to provide maintenance therapy and analgesia. - Opioid dependence: maintenance therapy reduces withdrawal symptoms and supports long‑term abstinence. - Severe chronic pain: provides long‑acting analgesia for patients with persistent pain unresponsive to other opioids. - Opioid detoxification: facilitates a controlled tapering process during supervised withdrawal programs.

Methadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Drowsiness: sedation or fatigue. - Nausea: upset stomach and possible vomiting. - Sweating: increased perspiration. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Cardiac arrhythmia: QT interval prolongation leading to irregular heartbeats. - Severe hypotension: marked drop in blood pressure. - Seizures: convulsive episodes, especially with high doses or interactions.

When prescribing Metadon, clinicians should observe several safety measures. - Assess patient history: evaluate prior opioid use, dependence risk, and comorbidities. - Monitor cardiac function: obtain baseline ECG and watch for QT prolongation. - Adjust dose cautiously: titrate slowly under medical supervision to avoid accumulation. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Educate on overdose risk: advise patients to seek immediate help if breathing slows. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Methadon can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase methadone plasma levels and toxicity. - QT‑prolonging agents (e.g., haloperidol, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2B6 inducers (e.g., rifampin, carbamazepine): may reduce methadone concentrations, lowering efficacy. - Antidepressants (e.g., SSRIs, SNRIs): can affect methadone metabolism and increase side‑effect potential. - Alcohol: potentiates sedative effects and respiratory depression. - Herbal supplements (e.g., St. John’s wort): may alter methadone metabolism.